Global Short-Read Sequencing Market to Reach $34.4 Billion by 2030
The global market for Short-Read Sequencing estimated at US$17.9 Billion in the year 2022, is projected to reach a revised size of US$34.4 Billion by 2030, growing at a CAGR of 8.5% over the analysis period 2022-2030. Next-Generation Sequencing, one of the segments analyzed in the report, is projected to record 8% CAGR and reach US$22.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Sanger Sequencing segment is readjusted to a revised 9.4% CAGR for the next 8-year period.
The U.S. Market is Estimated at $5.3 Billion, While China is Forecast to Grow at 7.6% CAGR
The Short-Read Sequencing market in the U.S. is estimated at US$5.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$5.8 Billion by the year 2030 trailing a CAGR of 7.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.5% and 6.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.Select Competitors (Total 32 Featured) -
- 10x Genomics
- Agilent Technologies, Inc.
- BGI
- Eurofins Scientific
- F. Hoffmann-La Roche Ltd
- Fasteris
- General Electric
- Genewiz
- GenScript
- Illumina, Inc
- Macrogen, Inc
- Qiagen
- Thermo Fisher Scientific, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Short-Read Sequencing - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Short-Read Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World 8-Year Perspective for Short-Read Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
- Table 3: World Recent Past, Current & Future Analysis for Next-Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 4: World 8-Year Perspective for Next-Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Sanger Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 6: World 8-Year Perspective for Sanger Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World 8-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 9: World Recent Past, Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 10: World 8-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Clinical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 12: World 8-Year Perspective for Clinical Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 14: World 8-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 15: World Recent Past, Current & Future Analysis for Pharma & Biotech Entities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 16: World 8-Year Perspective for Pharma & Biotech Entities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 18: World 8-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 20: World 8-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 21: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 22: World 8-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 23: World Short-Read Sequencing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
UNITED STATES
- Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 24: USA Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 25: USA 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
- Table 26: USA Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 27: USA 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
- Table 28: USA Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 29: USA 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
CANADA
- Table 30: Canada Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 31: Canada 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
- Table 32: Canada Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: Canada 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
- Table 34: Canada Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 35: Canada 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
JAPAN
- Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 36: Japan Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 37: Japan 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
- Table 38: Japan Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Japan 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
- Table 40: Japan Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 41: Japan 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
CHINA
- Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 42: China Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 43: China 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
- Table 44: China Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: China 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
- Table 46: China Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 47: China 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
EUROPE
- Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 48: Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 49: Europe 8-Year Perspective for Short-Read Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
- Table 50: Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: Europe 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
- Table 52: Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 53: Europe 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
- Table 54: Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 55: Europe 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
FRANCE
- Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 56: France Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: France 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
- Table 58: France Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 59: France 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
- Table 60: France Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 61: France 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
GERMANY
- Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 62: Germany Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: Germany 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
- Table 64: Germany Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 65: Germany 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
- Table 66: Germany Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 67: Germany 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
ITALY
- Table 68: Italy Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Italy 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
- Table 70: Italy Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 71: Italy 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
- Table 72: Italy Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 73: Italy 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
UNITED KINGDOM
- Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 74: UK Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: UK 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
- Table 76: UK Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 77: UK 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
- Table 78: UK Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 79: UK 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
REST OF EUROPE
- Table 80: Rest of Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: Rest of Europe 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
- Table 82: Rest of Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 83: Rest of Europe 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
- Table 84: Rest of Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 85: Rest of Europe 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
ASIA-PACIFIC
- Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Asia-Pacific 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
- Table 88: Asia-Pacific Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 89: Asia-Pacific 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
- Table 90: Asia-Pacific Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 91: Asia-Pacific 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
REST OF WORLD
- Table 92: Rest of World Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Rest of World 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2023 & 2030
- Table 94: Rest of World Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 95: Rest of World 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2023 & 2030
- Table 96: Rest of World Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 97: Rest of World 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 10x Genomics
- Agilent Technologies, Inc.
- BGI
- Eurofins Scientific
- F. Hoffmann-La Roche Ltd
- Fasteris
- General Electric
- Genewiz
- GenScript
- Illumina, Inc
- Macrogen, Inc
- Qiagen
- Thermo Fisher Scientific, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 88 |
| Published | April 2024 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 17.9 Billion |
| Forecasted Market Value ( USD | $ 34.4 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
